Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)

Abstract Background Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients with breast cancer (BC). Methods PALLAS is an open,...

全面介紹

書目詳細資料

Principais autores:	Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martin, Justin M. Balko, Zbigniew Nowecki, Marija Balic, Adam M. Brufsky, Arlene Chan, Patrick G. Morris, Tufia Haddad, Sibylle Loibl, Yuan Liu, Lidija Soelkner, Christian Fesl, Erica L. Mayer, Michael Gnant, on behalf of the PALLAS groups and investigators
格式:	Artigo
語言:	Inglês
出版:	BMC 2024-10-01
叢編:	Breast Cancer Research
主題:	Breast cancer HER2-low Palbociclib Endocrine therapy Antibody–drug conjugates
在線閱讀:	https://doi.org/10.1186/s13058-024-01899-2
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!